LABQUALITY

External Quality Assessment Schemes

Chlamydia pneumoniae, antibodies
EQA round 2, 2017

Thank you for participating in this EQA round.
The specimens were sent to 58 laboratories out of 19 countries. 54 of the laboratories returned their results on time.

Specimens
The survey included three plasma specimens with human origin; one single sample S001 and paired serum specimens S002 + S003. The specimens were distributed to the participants by mail without any temperature control. The instruction was to analyse the specimens as soon as possible, but within one week.
The specimens should have been stored in 2…8 °C.

A range of pre-distribution tests were performed in two reference laboratories. The used methods and the results are as follows:

Specimen S001:	S-CpnAbG:	Positive (low)
LQ757417021	S-CpnAbM:	Positive
	S-CpnAbA:	Negative

Clinical interpretations of the single serum sample S001:
Acute/recent Chlamydia pneumoniae infection.

Paired serum specimens 002 and 003

Specimen S002:	S-CpnAbG:	Positive
LQ757417022	S-CpnAbM:	Negative
	S-CpnAbA:	Positive (low)
Specimen S003:	S-CpnAbG:	Positive
LQ757417023	S-CpnAbM:	Negative
	S-CpnAbA:	Positive (low)

Clinical interpretation for the paired serum specimens S002 and S003:
Exposed to Chlamydia pneumoniae.

The specimens were pre-screened by one In house IF test method and one commercial (Labsystems) EIA-test method.

The results of *Chlamydia pneumoniae* antibody testing by different methods and the clinical interpretations are shown in the laboratory-specific tables. Acceptable results are indicated in the tables by arrows. The grey areas show the own results of the laboratory.

Please check that the client code on the print-out showing your results is correct (in top right-hand corner).

Comments

Specimen 001 (LQ757417021) contained low level of *C. pneumoniae* IgG and IgM antibodies. Altogether 37/50 of the performed tests could detect the IgM response (positive/weak positive) and 45/52 detected the IgG response.
78 % (107/137) of the participating laboratories reported expected test results.

Clinical interpretation: Acute/recent *Chlamydia pneumoniae* infection.
33 laboratories reported "Acute/recent *C. pneumoniae* infection", eleven reported "Exposed to *C.pneumoniae"*, five "Antibody findings not diagnostic" and two laboratories "No detectable *C.pneumoniae* antibodies.

2017-11-06

Final report

Items sent	2017-05-16
Round closed	2017-06-06
Preliminary results released	2017-06-09
Report released	2017-11-06

Product no. 5620
/FI
LQ757417021- LQ757417023

Subcontracting: Sample pretesting

The report contains
Expected results of the specimens, scheme expert comments and individual result tables.

Request for corrections
If your printouts are incomplete or contain incorrect data, you may obtain new corrected printouts by contacting us latest two weeks starting the date of printouts.

Scheme expert:
Mirja Puolakkainen, MD, PhD
Haartman Institute,
Department of Virology,
University of Helsinki

Authorized by
EQA Coordinator
Raija Myllys, Labquality
Tel +358 9 8566 8221
Fax +385 9 8566 8280
raija.myllys@labquality.fi

Next dispatch
The next *Chlamydia pneumoniae* antibodies round will be carried out in August 2017.

Labquality
Kumpulantie 15
FI-00520 Helsinki FINLAND
Telephone
international +358 9 8566 8200
FAX
international +358 9 8566 8280

info@labquality.fi
www.labquality.fi

FINAS
Finnish Accreditation Service
PT02 (EN ISO/IEC 17043)

Paired serum specimens 002 and 003

In pre-testing these paired specimens contained similar levels of IgG and IgA antibodies (no diagnostic titer changes) and the IgM antibodies were negative.

Specimen 002 (LQ757417022) contained *C. pneumoniae* IgG and IgA antibodies but no IgM antibodies. 94 % (126/134) of the participating laboratories reported expected IgG, IgA and IgM test results.

Specimen 003 (LQ757417023) contained *C. pneumoniae* IgG and IgA antibodies but no IgM antibodies. 95 % (127/134) of the participating laboratories reported expected IgG, IgA and IgM test results.

Expected clinical interpretation, paired specimens S002 and S003:

Majority 85 % (45/53) of the given clinical interpretations were correct/expected; 38 laboratories interpreted findings compatible with "Exposed to *Chlamydia pneumonia"*, one with "No indication of acute infection", one with "No IgM antibodies" and five with "Antibody findings not diagnostic". Six laboratories reported "Acute/recent *C. pneumoniae* infection" and one laboratory didn't report a clinical interpretation.

Scoring

Scoring is based on the clinical interpretations.
Exception: Laboratories that did not give clinical interpretations were scored based on their individual test results.

If less than 60 % of the test results are correct/expected the sample or the test in question will not be scored.

Specimen	No detectable *C.pneumoniae* antibodies	Exposed to *C.pneumoniae*	Acute/recent *C.pneumoniae* infection (reinfection)	Results not reported
S001	0	2	4	0
S002 + S003	0	4	2	0

Exception: -

Maximum score of the *Chlamydia pneumonia* antibodies EQA round 2, 2017 is 8/8.

Score summary	Mean *	Number of cl.interpretations
All participants	6,8	54

* Scores of the laboratories not reported their results are not included.

The reports and result tables of this round will be also available at Labqualitys homepage (www.labquality.fi). Please login to LabScala, fill in your laboratory's client code/personal user name and password. Then please choose My documents → View Reports.

End of report.